Follow

‘Unprecedented’, ‘Remarkable’: Cancer Study Leaves Every Patient Cancer-Free

A paper published on Sunday at The New England Journal of Medicine outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient who is now two years out from the trial.

dailywire.com/news/unprecedent

Sign in to participate in the conversation
No Agenda Social

The social network of the future: No ads, no corporate surveillance, ethical design, and decentralization! Own your data with Mastodon!